Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor endothelial up-regulation of IDO1 limits the response to CD40-stimulating immunotherapy

ABSTRACT: CD40-stimulating immunotherapy elicits potent anti-tumor responses, which are mainly T-cell dependent. Here, we have investigated how tumor endothelial cells respond to CD40-stimulating immunotherapy by isolating endothelial cells from B16.F10 melanoma in anti-CD40 treated or isotype treated mice followed by RNA-sequencing. Gene set enrichment analysis revealed an increase in interferon- related responses in tumor endothelial cells following anti-CD40 therapy. The immunosuppressive enzyme indoleamine 2, 3-dioxygenase 1 (IDO1) was preferentially expressed in endothelial cells, and it was up-regulated upon anti-CD40 treatment. IDO1 expression in tumor endothelium was positively correlated to T-cell infiltration and to increased expression of IFNγ in the tumor microenvironment. In vitro, endothelial cells up-regulated IDO1 in response to T-cell-derived IFNγ, but not in response to CD40-stimulation. Combining agonistic anti-CD40 therapy with the IDO1 inhibitor epacadostat delayed tumor growth and increased survival in B16.F10 tumor-bearing mice, which was associated with increased activation of tumor-infiltrating T-cells. Hereby, we have uncovered an immunosuppressive feedback mechanism, in which tumor vessels limit the efficacy of cancer immunotherapy by up-regulating IDO1 in response to T-cell activation.

ORGANISM(S): Mus musculus

PROVIDER: GSE130679 | GEO | 2020/04/06

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Tumor endothelial up-regulation of IDO1 limits the response to CD40-stimulating immunotherapy

Project description:Tumor endothelial up-regulation of IDO1 limits the response to CD40-stimulating immunotherapy

| PRJNA540971 | ENA

proteome analysis of Lung tissue of mice bearing B16-F10-luc-G5 melanoma tumor with sleep fragmentation and with or with out the asdmistration of GL-pp

Project description:Proteome analysis of Lung tissue of mice bearing B16-F10-luc-G5 melanoma tumor with sleep fragmentation and with or with out the asdmistration of GL-pp. The mice were randomly divided into 4 groups: control group in general condition with no further treatment (CON group), tumor group with the burden of B16-F10-luc-G5 cells (Tumor group), T+SF group with SF and the burden of B16-F10-luc-G5 cells (T+SF group), and GL-pp group with SF, tumor cells burden, and the administration of 80 mg/kg GL-pp (GL-pp group). B16-F10-luc-G5 cells (5 × 1000000 cells/100 µL per mouse) were injected into the mice through the tail vein. The lung tissue of T+SF group and GL-pp group were analyzed by the proteome.

2021-09-10 | PXD025171 | Pride

Transcription profiling of mouse model of melanome secreting different amounts of histidine

Project description:We previously showed that transgenic enhancement of histamine production in B16-F10 melanomas strongly supports tumor growth in C57Bl/6 mice (Cancer Res, 2005 Pos et al.). In this array experiment, gene expression profiles of transgenic mouse melanomas, secreting different amounts of histamine, were compared by whole genome microarrays. Experiment Overall Design: By modifying the levels of L-histidine decarboxylase (HDC), the sole enzyme responsible for histamine production, we introduced three novel variants of the B16-F10 mouse melanoma cell line, displaying diminished (B16-F10 HDC-A), unmodified (B16-F10 HDC-M) or enhanced (B16-F10 HDC-S) capacities to produce and secrete histamine. Experiment Overall Design: In this experiment, B16-F10 HDC-A, HDC-M, and HDC-S experimental mouse melanomas were compared by analyzing 6-6 tumors in each group. Experiment Overall Design: In order to reduce the amount of arrays required, equal amounts of randomly chosen RNA sample pairs were pooled in each group, thus, at the end, each group consisted of 3 pooled tumor samples. All samples were biological replicates, no technical replicates or dye swapping were done. Experiment Overall Design: Gene expression patterns of the three tumor groups were compared indirectly, via a common reference samplei n a two-color array design. Arrays shown here represent gene expression patterns of individual tumor samples compared to the reference sample.

2008-06-16 | E-GEOD-8541 | biostudies-arrayexpress

Anti-tumor immunity induces the presentation of aberrant peptides in melanoma

Project description:Extensive tumor inflammation, reflected by high levels of infiltrating T-cells and Interferon gamma (IFNγ) signaling, is thought to improve checkpoint immunotherapy response. However, many tumors escape by activating multiple cellular pathways that induce immunosuppression. One pivotal immune-suppressive mechanism is the production of Tryptophan metabolites along the kynurenine pathway by IFNγ-induced IDO1 enzyme production. However, phase III clinical trials using chemical inhibition of IDO1 in combination with PD1 pathway blockade failed to improve melanoma treatment, suggesting incomplete understanding of the role of IDO1 and the consequent Tryptophan degradation on mRNA translation and cancer progression. Here, we investigated the effects of prolonged IFNγ treatment on mRNA translation in melanoma cells by ribosome profiling. Our results suggest that IFNγ-induced IDO1-mediated Tryptophan depletion may play a key role in the immune recognition of melanoma cells, by inducing the production and presentation of aberrant peptides.

2020-10-18 | GSE142822 | GEO

An Irf2-expressing oncolytic virus changes the susceptibility of tumor to antitumor T cells and promotes promotes tumor clearance

Project description:According to our previous studies, IRF1-deficient (IRF1-KO) tumor cells showed significantly reduced tumor growth when injected in several syngeneic mouse models including the B16-F10 melanoma, indicating that tumor cells require IRF1 for sustained tumor progression. Depletion of CD8+ T cells or NK cells could restore tumor growth of IRF1-KO cells. In addition, we found that loss of IRF1 in tumor cells could decrease the IFNγ-induced expression of PD-L1. To examine if IRF1 can be a target for cancer immunotherapy, we attempted to comprehensively identify genes that are specifically regulated by IRF1 in tumor cells that contribute to the tumor progression and the suppression of immune surveillance. Our RNA-seq data suggest that IRF1 regulates not only the expression of immune inhibitory ligands, but also the production of class I MHC molecules.

2024-03-18 | GSE261564 | GEO

Transcriptomics of PTEN knockout B16-F10 cells in C57BL/6J mice model treated with PTEN

Project description:extracellular PTEN treatment did not affect the growth of PTEN knockout B16-F10 cells cultured in vitro. , To investigate whether extracellular PTEN act on the tumor microenvironment to exert a tumor-suppressive role in vivo，molecular changes caused by PTEN treatment inside the B16-F10-PTEN tumors were monitored by RNA sequencing.

2024-07-24 | GSE249142 | GEO

Mass spectrometry analysis of proteins interacting with STC1

Project description:identify the potential partners of STC1 at the protein level, we performed mass spectrometry on B16-F10 tumor cells stably expressing FLAG-tagged STC1.

2020-12-23 | PXD023251 | Pride

Endothelial Pim3 kinase protects the vascular barrier during lung metastasis

Project description:To investigate transcriptome changes of endothelial cells during cancer cell response, we studied HUVEC RNA expression in conditioned medium derived from empty plates versus B16-F10 melanoma cultures.

2024-09-11 | GSE251979 | GEO

Gene Expression in wild type and CCR5 knockout mice with lung metastasis

Project description:We have shown that C57BL/6J CCR5 knockout mice develop 30.4% ± 8.6% fewer B16 F10 lung nodules compared to wild type mice after the intravenous injection of 100,000 B16 F10 cells. We sought to understand this phenomenon by comparing gene expression in the lungs of these mice at 6, 24, and 48 hours after tumor injection.

2013-10-25 | GSE51422 | GEO

Identification of tumor membrane proteins

Project description:Identification of chemotherapy-treated B16-F10 tumor membrane proteins

2024-08-28 | PXD055424 |